ZG 033
Alternative Names: ZG-033Latest Information Update: 09 Jun 2023
Price :
$50 *
At a glance
- Originator Hefei HankeMab Biotechnology
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 14 Apr 2023 Phase-I clinical trials in Cancer (Parenteral) before April 2023
- 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical studies in Cancer were presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 08 Apr 2022 Preclinical trials in Cancer in China (Parenteral), prior to April 2022